Article Text

other Versions

Download PDFPDF
Anti-tumor necrosis factor therapy in patients with refractory Takayasu’s arteritis: long-term follow-up
  1. Eamonn S Molloy (eamonn.molloy{at}
  1. Cleveland Clinic, United States
    1. Carol A Langford (langfoc{at}
    1. Cleveland Clinic, United States
      1. Tiffany M Clark (clarkt{at}
      1. Cleveland Clinic, United States
        1. Carmen E Gota (gotac{at}
        1. Cleveland Clinic, United States
          1. Gary S Hoffman (hoffmag{at}
          1. Cleveland Clinic, United States


            Objective: Assess the efficacy of anti-tumor necrosis factor (TNF) therapy to induce remission in patients with Takayasu’s arteritis (TAK) refractory to other immunosuppressive therapies.

            Methods: Retrospective single-center study of 25 patients with refractory TAK.

            Results: Patients were treated with infliximab (IFX) or etanercept (ETA) for up to 7 years; 21 with IFX [median 28 (range 2-84) months] and 9 with ETA [median 28 (range 4-82) months]; 5 patients initially treated with ETA subsequently switched to IFX. Following anti-TNF therapy, remission was achieved and prednisone was discontinued in 15 patients (60%) and successfully tapered below 10mg per day in an additional 7 patients (28%). Of 18 patients treated with other immunosuppressive agents concurrent with anti-TNF therapy, 9 (50%) could taper or discontinue the additional agent. Major relapses occurred in 4 patients that initially achieved stable remission. Four patients suffered adverse events, including 1 with opportunistic infections and 1 with breast cancer.

            Conclusions: In this group of patients with refractory TAK, anti-TNF therapy was associated with remission in a majority of patients, facilitating dose reduction or discontinuation of prednisone and other immunosuppressive therapy. These findings strengthen the rationale for the conduct of a randomized controlled trial of anti-TNF therapy in TAK.

            Statistics from

            Request Permissions

            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.